Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa

Pediatric Pulmonology

Volumn 47, Issue 7, 2012, Pages 641-648

  Saiman, Lisa ^a   Mayer Hamblett, Nicole ^b,c   Anstead, Michael ^d   Lands, Larry C ^e   Kloster, Margaret ^c,d   Goss, Christopher H ^c,d,f   Rose, Lynn M ^b,c   Burns, Jane L ^b,c   Marshall, Bruce C ^g,h   Ratjen, Felix ⁱ  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF WASHINGTON   (United States)

^g CYSTIC FIBROSIS FOUNDATION   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

azithromycin; cystic fibrosis; durability of treatment response; macrolide antibiotics

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MICROBIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84862179762     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21601     Document Type: Article

References (15)

1. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J,. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial. Thorax 2002; 57: 212-216.
2. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M,. Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial. Lancet 2002; 360: 978-984.
3. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2003; 290: 1749-1756.
4. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP,. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 2006; 61: 895-902.
5. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2010; 303: 1707-1715.
6. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG, Jr., Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15: 75-88.
7. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
8. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR,. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998; 27: 158-163.
9. Diggle P, Heagerty P, Liang KY, Zeger S,. Analysis of longitudinal data. Oxford, UK: Oxford University Press; 2002.
10. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK,. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: Long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007; 26: 8-12.
11. Southern KW, Barker PM, Solis-Moya A, Patel L,. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004; Issue 2, Art. No.: CD002203. DOI: 10.1002/14651858.CD002203.pub2
12. Yousef AA, Jaffe A,. The role of azithromycin in patients with cystic fibrosis. Paediatr Respir Rev 2010; 11: 108-114.
13. Hansen CR, Pressler T, Hoiby N, Johansen HK,. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros 2009; 8: 58-62.
14. Saiman L,. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004; 10: 515-523.
15. Green N, Burns JL, Mayer-Hamblett N, Kloster M, Lands LC, Anstead M, Ratjen F, Saiman L,. Lack of association of small-colony-variant Staphylococcus aureus strians with long term use of azithromycin in patients with cystic fibrosis. J Clin Microbiol 2011; 49: 2772-2773.